Christopher Garabedian

2012

In 2012, Christopher Garabedian earned a total compensation of $2.6M as Former President and Chief Executive Officer at Sarepta Therapeutics, a 32% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$318,500
Option Awards$1,741,757
Salary$490,000
Stock Awards$73,500
Other$16,754
Total$2,640,511

Garabedian received $1.7M in option awards, accounting for 66% of the total pay in 2012.

Garabedian also received $318.5K in non-equity incentive plan, $490K in salary, $73.5K in stock awards and $16.8K in other compensation.

Rankings

In 2012, Christopher Garabedian's compensation ranked 2,674th out of 11,487 executives tracked by ExecPay. In other words, Garabedian earned more than 76.7% of executives.

ClassificationRankingPercentile
All
2,674
out of 11,487
77th
Division
Manufacturing
941
out of 4,253
78th
Major group
Chemicals And Allied Products
212
out of 1,198
82nd
Industry group
Drugs
125
out of 920
86th
Industry
Pharmaceutical Preparations
102
out of 700
85th
Source: SEC filing on April 30, 2015.

Garabedian's colleagues

We found seven more compensation records of executives who worked with Christopher Garabedian at Sarepta Therapeutics in 2012.

2012

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2012

David Howton

Sarepta Therapeutics

General Counsel

2012

David Howton

Sarepta Therapeutics

General Counsel

2012

Edward Kaye

Sarepta Therapeutics

Chief Executive Officer

2012

Michael Jacobsen

Sarepta Therapeutics

Vice President, Finance

2012

Jayant Aphale

Sarepta Therapeutics

Senior Vice President, Technical Operations

2012

Effie Toshav

Sarepta Therapeutics

General Counsel

In-depth

You may also like